Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ion Beam ApplicationsIOBCF 82 Cash-to-Debt is 0.56 as of Dec. 2025, which is 67% below its 10-year median of 1.71. GuruFocus rates IOBCF with a GF Score™ of 82/100 and a GF Value™ of $18.67 (Fairly Valued). The stock has 9 warning signs investors should review. Among 849 Medical Devices & Instruments companies, Ion Beam Applications ranks worse than 70.08% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Ion Beam Applications's cash to debt ratio for the quarter that ended in Dec. 2025 was 0.56.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Ion Beam Applicationscouldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for Ion Beam Applications's Cash-to-Debt or its related term are showing as below:
IOBCF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.37 Med: 1.71 Max: 4.19
Current: 0.56
During the past 13 years, Ion Beam Applications's highest Cash to Debt Ratio was 4.19. The lowest was 0.37. And the median was 1.71.
IOBCF's Cash-to-Debt is ranked worse than 70.08% of 849
companies
in the Medical Devices & Instruments industry
Industry Median: 1.64
vs IOBCF: 0.56
Ion Beam Applications (OTCPK:IOBCF) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Ion Beam Applications Cash-to-Debt Related Terms
Ion Beam Applications Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Ion Beam Applications's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Medical Devices subindustry, Ion Beam Applications's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ion Beam Applications Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ion Beam Applications's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Ion Beam Applications's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ion Beam Applications (IOBCF) has a Cash-to-Debt of 0.56 as of Dec. 2025. This is 67% below median its historical median of 1.71. Over the past decade, Ion Beam Applications' Cash-to-Debt has ranged from 0.37 to 4.19. According to the industry distribution chart, Ion Beam Applications ranks #595 out of 849 companies in the Medical Devices & Instruments industry, placing it in the top 70.1%.
Is Ion Beam Applications' Cash-to-Debt too high?
Ion Beam Applications' current Cash-to-Debt of 0.56 is 67% below median its 10-year median of 1.71. Over the past 10 years, this metric has ranged from a low of 0.37 to a high of 4.19. The Medical Devices & Instruments industry median Cash-to-Debt is 1.64. Ion Beam Applications' value of 0.56 is 65.9% below this industry median. Based on the distribution chart, Ion Beam Applications ranks #595 out of 849 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Ion Beam Applications has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ion Beam Applications' Cash-to-Debt compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Ion Beam Applications ranks #595 out of 849 companies for Cash-to-Debt. This places Ion Beam Applications in the lower half of its industry. The industry median Cash-to-Debt is 1.64. Ion Beam Applications' value of 0.56 is 65.9% below this benchmark. Historically, Ion Beam Applications' own Cash-to-Debt has ranged from 0.37 to 4.19 over the past decade. While the company's 10-year median is 1.71 vs. the industry median of 1.64, Ion Beam Applications has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.64, based on 849 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ion Beam Applications's current Cash-to-Debt of 0.56 is 65.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ion Beam Applications's current Cash-to-Debt is 0.56, which is 67% below median its own 10-year median of 1.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ion Beam Applications stock overvalued right now?
Based on GuruFocus' analysis, Ion Beam Applications (IOBCF) is currently considered Fairly Valued. The stock's GF Value™ is $18.67, compared to a current price of $17.93 — trading 4% below its estimated fair value. The current Cash-to-Debt is 0.56, which is 67% below median its 10-year median of 1.71 and 65.9% below the Medical Devices & Instruments industry median of 1.64. Ion Beam Applications' overall GF Score™ is 82/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Ion Beam Applications (IOBCF), the current Cash-to-Debt is 0.56 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ion Beam Applications (IOBCF) Overvalued in 2026?
Based on GuruFocus' analysis, Ion Beam Applications stock appears to be undervalued.
The current stock price of $17.93 is trading 4% below its estimated GF Value™ of $18.67.
GuruFocus considers Ion Beam Applications to be Fairly Valued.
Key valuation signals for IOBCF:
Cash-to-Debt: 0.56 (67% below median its 10-year median of 1.71)
GF Value™: $18.67 vs. price of $17.93 (4% below fair value)
Industry Position: 65.9% below the Medical Devices & Instruments median (#595 of 849)
No single metric tells the full story. See the IOBCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ion Beam Applications SA develops and manufactures medical devices and software solutions. The firm operates in three segments: IBA Clinical, including Proton Therapy and Dosimetry; IBA Technologies; and IBA Corporate. Proton therapy and other accelerators contribute to the majority of sales. It offers solutions for precision cancer treatment through the use of proton beams, as well as cyclotrons used for the production of radioisotopes and industrial accelerators for sterilization and ionization. The dosimetry business sells measurement and quality assurance instruments for radiotherapy and medical imaging. The firm operates in three geographical areas: Belgium, the United States, China, Germany, and India.
82GF Score
Get the complete analysis for IOBCF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IOBCF has been successfully added to your 
